Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 ENTEREG ® (Alvimopan) Part 1: Efficacy and General Safety Evaluation Clinical Evaluation of NDA 21-775 ENTEREG ® (Alvimopan) Part 1: Efficacy and General.

Published byBlaze Gregory Modified over 8 years ago

Similar presentations

Presentation on theme: "1 ENTEREG ® (Alvimopan) Part 1: Efficacy and General Safety Evaluation Clinical Evaluation of NDA 21-775 ENTEREG ® (Alvimopan) Part 1: Efficacy and General."— Presentation transcript:

1 1 ENTEREG ® (Alvimopan) Part 1: Efficacy and General Safety Evaluation Clinical Evaluation of NDA 21-775 ENTEREG ® (Alvimopan) Part 1: Efficacy and General Safety Evaluation Ruyi He, MD Medical Team Leader Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting January 23, 2008

2 2 Overview of Presentation  Part 1: Efficacy and General Safety  Alvimopan and POI  Regulatory History  POI Clinical Program  POI Efficacy Results  POI General Safety Results  OBD Clinical Program  Part 2: Special Safety Issues  Part 3: Non-Clinical Evaluation  Part 4: Risk Management

3 3 Alvimopan  New Molecular Entity  Peripherally-acting opioid-receptor antagonist  Low systemic oral bioavailability (about 6%)  T max about 2 h. Half Life ranged from 4 to 17 h  One active metabolite (ADL 08-0011).

4 4 Sponsor’s Proposed Indication Acceleration of time to upper and lower gastrointestinal (GI) recovery following partial large and small bowel resection surgery with primary anastomosis

5 5 Postoperative ileus (POI)  Transient impairment of GI function after surgery  Characterized by inability to tolerate liquids and solid food, nausea, vomiting, and/or abdominal pain/bloating  Complications include prolonged hospitalization, delayed nutrition, et al.  No product is currently approved for POI in the U.S.  Off-label therapies include metoclopramide and erythromycin

6 6 Main Regulatory History DateEvent Aug. 1998Initial IND submitted Feb. 2004Fast Track Designation granted for POI June 2004 Original NDA 21-775 submitted July 2005 Approvable action, insufficient evidence for efficacy May 2006 Complete response submitted, serious CV events noted in an ongoing OBD study Nov. 2006 2 nd approvable action, requested final 12m safety findings and risk management plan April 2007 Full clinical hold; CV events, neoplasms and bone fractures were identified in OBD studies Aug. 2007 Complete response submitted. PDUFA due day: 2/10/08

7 7 POI Clinical Program Six Phase 3 Clinical Studies (302, 306, 308, 313, 001 and 314): Randomized, double-blind, placebo-controlled, multi centered trials in patients undergoing partial large or small BR or total abdominal hysterectomy (TAH) surgery. Study 001 was conducted in Europe and Australia. All other studies were conducted in the US and Canada. Patients on chronic opioids were excluded from the studies.

8 8 POI Clinical Program Since efficacy was not demonstrated in the TAH surgery subgroup in the original NDA submission, the sponsor decided to narrow proposed indication to the BR surgery population only Study 306 is not included in the efficacy evaluation, because no BR patient was enrolled in this study (TAH only)

9 9 Treatment  Initial Dose given 0.5 to 2 h prior to surgery, Subsequent Doses: 12 mg PO, BID from POD 1 until hospital discharge or POD 7  Maximum number of doses is 15 (maximum of 8 days of therapy)  Study drugs only administered in hospital

10 10 Key Endpoints  GI-3: time from end of surgery to time of recovery of both upper and lower GI tract function  Toleration of solid food;  First BM or flatus;  It was the primary EP for Study 302, 308, 313 and 001.  GI-2 (solid food, first BM).  GI-2 was the primary EP for Study 314.  GI-2 maybe a more objective EP than GI-3.  Ready: time from end of surgery to time ready for hospital discharge based solely on recovery of GI function as defined by the surgeon.  DOW: time from end of surgery to time discharge order is written.

11 11 GI-3 Recovery: Difference from Placebo (Hours)* in BR Patients Study302308 313001314 25 th percentile 4.611.36.73.412.2 Median 7.613.410.54.49.1 75 th percentile 7.520.72114.115.5 HR (95% CI) 1.295 (0.96, 1.74) 1.317 (1.03, 1.69) 1.494 (1.17, 1.91) 1.132 (0.94, 1.37) 1.45 (1.23, 1.71) P-value 0.0860.0290.0010.200<0.001 *Using Cox Proportional Hazards Models

12 12 GI-2 Recovery: Difference from Placebo (Hours)* in BR Patients Study302308313001314 25 th percentile 11.55.314.12.89.2 Median 1713.821.74.416.6 75 th percentile 19.521.328.918.720.3 HR (95% CI) 1.40 (1.04, 1.89) 1.37 (1.06, 1.76) 1.63 (1.26, 2.10) 1.30 (1.07, 1.58) 1.53 (1.29, 1.82) P-value 0.0290.017<0.0010.008<0.001 *Using Cox Proportional Hazards Models

13 13 Ready: Difference from Placebo (Hours)* in BR Patients Study302308313001314 25 th percentile 7.75.512.85.33.2 Median 14.58.017.310.310.6 75 th percentile 20.320.424.56.521.1 HR (95% CI) 1.52 (1.11, 2.09) 1.40 (1.09, 1.78) 1.54 (1.20, 1.96) 1.11 (0.92, 1.35) 1.38 (1.17, 1.63) P-value 0.0100.008<0.0010.287<0.001 *Using Cox Proportional Hazards Models

14 14 Time to DOW (Days)* in BR Patients StudyTxMedianΔ 75 th Percentile Δ HR (95% CI) p-value 302 PL Alv 5.6 4.9 0.7 6.8 6.0 0.8 1.29 (0.98, 1.7) 0.084 308 PL Alv 5.7 5.0 0.7 7.2 6.0 1.2 1.56 (1.2, 2.0) <0.001 313 PL Alv 5.6 4.8 0.8 7.5 6.0 1.5 1.42 (1.1, 1.8) 0.004 001 PL Alv 8.0 0 11.1 10.9 0.2 1.07 (0.9, 1.3) 0.838 314 PL Alv 5.0 4.7 0.3 6.9 5.9 1.0 1.40 (1.2, 1.7) <0.001 *Using Cox Proportional Hazards Models

15 15 Mean Length of Hospital Stay (Days) Study302308313001314 Placebo 6.4 (n=99) 6.6 (n=142) 7.4 (n=142) 9.2 (n=229) 6.2 (n=312) Alvimopan 12 mg 6.1 (n=98) 5.7 (n=139) 6.1 (n=160) 8.9 (n=238) 5.2 (n=317) Difference0.30.91.30.21.0

16 16 Efficacy Summary in POI Efficacy data demonstrated: there was acceleration of recovery of upper and lower GI tract function by roughly 20 hours measured by GI2 and reduced length of hospital stay by roughly 1 day in the US.

17 17 Questions What is the minimum acceptable efficacy difference for recovery of GI function measured by GI2 or GI3 for alvimopan relative to placebo? 12h? 24h? 36h? other? Do you consider the efficacy results from the POI studies to be clinically meaningful?

18 18 General Safety Evaluation in the POI Population A total of 3975 patients are included in the POI safety database –1365 patients received placebo –2610 patients received alvimopan at doses of 1, 3, 6, or 12 mg

19 19 Demographics-Overall POI Population CharacteristicPla. N=1365 n (%) Alv. N=2610 n (%) Age, Mean5857 Age > 65 yr491 (36)898 (34.4) Race: White1156 (84.7)2207 (84.6) Other209 (15.3)403 (15.4) Female850 (62.3)1680 (64.4)

20 20 POI Safety: Deaths and SAEs n (%) Placebo (N=1365) Alv 6 mg (N=898) Alv 12 mg (N=1650) Total Deaths 9 (0.7)5 (0. 6)8 (0.5) All Nonfatal SAEs250 (18)110 (12)192 (12) POI/SBO 86 (6)18 (2)32 (2) Infection 19 (1)10 (1)18 (1) Anastomotic leak 15 (1)12 (1)11 (1) Pulmonary emboli 13 (1)9 (1)11 (1)

21 21 POI: AEs Leading to Discontinuations n (%) Placebo (N=1365) Alv. 6 mg (N=898) Alv. 12 mg (N=1650) Total162 (12)74 (8)125 (8) Nausea42 (3)19 (2)39 (2) Vomiting43 (3)17 (2)24 (2) POI45 (3)11 (1)20 (1) Abd. distension11 (1)6 (1)8 (1) Diarrhea4 (0.3)08 (0.5) Dyspepsia01 (0.1)8 (0.5)

22 22 Treatment-Emergent Events n (%) Placebo N=986 Alv. 6 mg N=663 Alv. 12 mg N=999 Nausea491 (49.8)246 (37.1)433 (43.3) Vomiting209 (21.2)111 (16.7)141 (14.1) Abd. distension137 (13.9)59 (8.9)120 (12) Pruritus97 (9.8)46 (6.9)85 (8.5) POI113 (11.5)33 (5)60 (6) Urinary retention21 (2.1)17 (2.6)32 (3.2) Pain18 (1.8)18 (2.7)12 (1.2) SBO18 (1.8)5 (0.8)9 (0.9) Anastomotic leak11 (1.1)8 (1.2)8 (0.8)

23 23 General Safety Summary in POI Similar or lower incidences of death, nonfatal SAEs, discontinuations due to AEs and treatment-emergent events were identified in the alvimopan groups in comparison with the placebo group in POI population

24 24 Chronic Opioid-Induced Bowel Dysfunction (OBD)  OBD is chronic condition characterized by decreased frequency of bowel movements and associated symptoms  Patients in OBD studies were treated for chronic pain with opioids for months, years; instead of days in POI  Although current submission is only for POI indication, imbalances in CV events, neoplasms and bone fractures were identified in OBD clinical studies

25 25 Regimen in POI & OBD Dose Regimen in POI & OBD POIOBD RouteOral Dose Regimen 12 mg BID (up to 7 days postop) 0.5 -1 mg QD or BID (up to one year) Maximum Daily Dose 24 mg/day1-2 mg/day DurationUp to 8 daysUp to 1 year LocationHospital onlyMostly Outpatient

26 26 Thank You  Eric Brodsky (Medical Reviewer)  Sonia Castillo (Statistician)  Joyce Korvick (Deputy Division Director)  Julie Beitz (Office Director)  Daniel Shames (Deputy Office Director)  Matthew Scherer (Projector Manager)  Sue Chih Lee (Biopharmaceutics)  Tamal Chakraborti (Pharmacologist)  Marie Kowblansky (Chemist)  And everyone in the review team

Download ppt "1 ENTEREG ® (Alvimopan) Part 1: Efficacy and General Safety Evaluation Clinical Evaluation of NDA 21-775 ENTEREG ® (Alvimopan) Part 1: Efficacy and General."

Similar presentations

Oncologic Drugs Advisory Committee

Oncologic Drugs Advisory Committee
Efficacy and Necessity of Nasojejunal Tube after Gasrectomy Presented by Dr. Sadjad Noorshafiee Resident of General Surgery Supervised by Dr.A.tavassoli.

Efficacy and Necessity of Nasojejunal Tube after Gasrectomy Presented by Dr. Sadjad Noorshafiee Resident of General Surgery Supervised by Dr.A.tavassoli.
Overview of the Clinical Development EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use. ASENT 12 th Annual.

Overview of the Clinical Development EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use. ASENT 12 th Annual.
Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,

Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345:1291-7. Incidence of CV events in women.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Robertson JFR et al. J Clin Oncol 2009;27(27):

Robertson JFR et al. J Clin Oncol 2009;27(27):
Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.

Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
Elective Colorectal Resection – How to Hasten the Recovery? Dr. Lily Ng RHTSK.

Elective Colorectal Resection – How to Hasten the Recovery? Dr. Lily Ng RHTSK.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
1Stopeck A et al. Proc SABCS 2010;Abstract P

1Stopeck A et al. Proc SABCS 2010;Abstract P
Rapivab™ - peramivir injection

Rapivab™ - peramivir injection
1 March 2003 ODAC: DOXIL ®, AIDS-KS ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment of.

1 March 2003 ODAC: DOXIL ®, AIDS-KS ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment of.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.

0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.

ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
1 ZELMAC (tegaserod) Presentation to GI Advisory Committee June 26, 2000 Raymond E. Joseph MD Medical Officer HFD-180.

1 ZELMAC (tegaserod) Presentation to GI Advisory Committee June 26, 2000 Raymond E. Joseph MD Medical Officer HFD-180.
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
1 FDA Review of NDA 21-304 Valganciclovir for the Treatment of CMV Retinitis in AIDS Joseph Toerner, MD Medical Officer DAVDP.

1 FDA Review of NDA Valganciclovir for the Treatment of CMV Retinitis in AIDS Joseph Toerner, MD Medical Officer DAVDP.
1 August 2003 Elements of a Profitable Biopharmacutical Company Roland E. Dolle September 24, 2003.

1 August 2003 Elements of a Profitable Biopharmacutical Company Roland E. Dolle September 24, 2003.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Similar presentations

Ads by Google